Iradimed Corp (IRMD) valuation
Iradimed P/E ratio history
Iradimed trades at 41.0 times its earnings over the last twelve months and 32.4 times the earnings analysts expect over the next twelve. At its last 10 fiscal year ends its P/E ranged from 18.5 (year to Dec 2016) to 378.8 (year to Dec 2017), with a median of 41.9.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $97.28 | $1.75 | 55.6 | 47.3 |
| Dec 31, 2024 | $55.00 | $1.50 | 36.7 | — |
| Dec 31, 2023 | $47.47 | $1.35 | 35.2 | 29.2 |
| Dec 31, 2022 | $28.29 | $1.02 | 27.7 | 23.4 |
| Dec 31, 2021 | $46.21 | $0.74 | 62.5 | 61.2 |
| Dec 31, 2020 | $22.80 | $0.11 | 207.3 | — |
| Dec 31, 2019 | $23.38 | $0.78 | 30.0 | — |
| Dec 31, 2018 | $24.46 | $0.52 | 47.0 | — |
| Dec 31, 2017 | $15.15 | $0.04 | 378.8 | — |
| Dec 31, 2016 | $11.10 | $0.60 | 18.5 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Iradimed valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| IradimedIRMD | $980M | 41.0 | 32.4 | 11.4 |
| HealthstreamHSTM | $985M | 46.8 | 41.7 | 3.1 |
| SavaraSVRA | $988M | — | — | — |
| Integra Lifesciences HoldingsIART | $992M | 79.7 | 5.4 | 0.6 |
| Oric PharmaceuticalsORIC | $957M | — | — | — |
| CeribellCBLL | $1.01B | — | — | 9.9 |
| Rigel PharmaceuticalsRIGL | $949M | 3.0 | 12.1 | 3.4 |
| Si BoneSIBN | $942M | — | — | 4.4 |
| Cullinan TherapeuticsCGEM | $924M | — | — | — |
| Peer median | 46.8 | 12.1 | 3.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: IRMD financials · IRMD returns
No forecast, no recommendation. This page describes Iradimed Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.